These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36737259)

  • 1. The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer.
    Naser-Tavakolian A; Venkataramana A; Spiegel B; Almario C; Kokorowski P; Freedland SJ; Anger JT; Leppert JT; Daskivich TJ
    Urol Oncol; 2023 Apr; 41(4):205.e1-205.e10. PubMed ID: 36737259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort.
    Vaculik K; Luu M; Howard LE; Aronson W; Terris M; Kane C; Amling C; Cooperberg M; Freedland SJ; Daskivich TJ
    JAMA Netw Open; 2021 Jun; 4(6):e2112214. PubMed ID: 34081138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer.
    Degeling K; Corcoran NM; Pereira-Salgado A; Hamid AA; Siva S; IJzerman MJ
    Value Health; 2021 Dec; 24(12):1737-1745. PubMed ID: 34838271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer.
    Dorth JA; Lee WR; Chino J; Abouassaly R; Ellis RJ; Myers ER
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):383-390. PubMed ID: 29353655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
    Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
    J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.
    Cooperberg MR; Ramakrishna NR; Duff SB; Hughes KE; Sadownik S; Smith JA; Tewari AK
    BJU Int; 2013 Mar; 111(3):437-50. PubMed ID: 23279038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.
    Boehm K; Dell'Oglio P; Tian Z; Capitanio U; Chun FKH; Tilki D; Haferkamp A; Saad F; Montorsi F; Graefen M; Karakiewicz PI
    World J Urol; 2017 Jul; 35(7):1031-1036. PubMed ID: 27796538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation.
    Sun M; Sammon JD; Becker A; Roghmann F; Tian Z; Kim SP; Larouche A; Abdollah F; Hu JC; Karakiewicz PI; Trinh QD
    BJU Int; 2014 Feb; 113(2):200-8. PubMed ID: 23937636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data.
    Würnschimmel C; Wenzel M; Wang N; Tian Z; Karakiewicz PI; Graefen M; Huland H; Tilki D
    Prostate; 2021 Aug; 81(11):785-793. PubMed ID: 34101879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy.
    Chen MS; Howard LE; Stock S; Dolgner A; Freedland SJ; Aronson W; Terris M; Klaassen Z; Kane C; Amling C; Cooperberg M; Daskivich TJ
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):715-721. PubMed ID: 35668181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
    Kang SK; Mali RD; Prabhu V; Ferket BS; Loeb S
    Radiology; 2021 Sep; 300(3):594-604. PubMed ID: 34254851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
    Govers TM; Caba L; Resnick MJ
    J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.
    Shao YH; Kim S; Moore DF; Shih W; Lin Y; Stein M; Kim IY; Lu-Yao GL
    Eur Urol; 2014 Apr; 65(4):693-700. PubMed ID: 23759328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do older men benefit from curative therapy of localized prostate cancer?
    Alibhai SM; Naglie G; Nam R; Trachtenberg J; Krahn MD
    J Clin Oncol; 2003 Sep; 21(17):3318-27. PubMed ID: 12947068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
    Sanghera S; Mohiuddin S; Coast J; Garfield K; Noble S; Metcalfe C; Lane JA; Turner EL; Neal D; Hamdy FC; Martin RM; Donovan JL;
    BMC Cancer; 2020 Oct; 20(1):971. PubMed ID: 33028256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence.
    Weng X; Zhong L; Xiang P; Li Y; Paciorek A; Dong L; Broering J; Carroll PR; Sanda M; Wilson L
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13740. PubMed ID: 36239065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the UK.
    Labban M; Dasgupta P; Song C; Becker R; Li Y; Kreaden US; Trinh QD
    JAMA Netw Open; 2022 Apr; 5(4):e225740. PubMed ID: 35377424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer.
    White C; Nimeh T; Gazelle GS; Weinstein MC; Loughlin KR
    Cancer; 2019 Mar; 125(6):952-962. PubMed ID: 30561761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables.
    Würnschimmel C; Nocera L; Wenzel M; Ruvolo CC; Tian Z; Saad F; Briganti A; Shariat SF; Mirone V; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
    J Racial Ethn Health Disparities; 2023 Apr; 10(2):708-717. PubMed ID: 35182370
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.